Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design
Study context
- Population
- Pregnant and postpartum women aged ≥18 seen for routine obstetric care in Nigeriaplanned enrolment
- Participants
- 1,000 participants
- Planned comparison
- AI-ECG screening vs control
- Primary endpoint
- New diagnosis of cardiomyopathy (left ventricular ejection fraction (LVEF) < 50%)
- Follow-up
- During pregnancy or within 12 months postpartum
Methodological detailsrationale and design, multicentre, 1:1 randomisation, 6 sites in Nigeria
- Rationale and design
- Multicentre
- 1:1 randomisation
- 6 sites in Nigeria
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design. Am Heart J. Published 25 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →